CNTB (Connect Biopharma Holdings) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.36
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings NonCurrent Deferred Liabilities?

Connect Biopharma Holdings CNTB +4.20% 7 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Connect Biopharma Holdings's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Connect Biopharma Holdings NonCurrent Deferred Liabilities Related Terms

Connect Biopharma Holdings NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings NonCurrent Deferred Liabilities Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.78 0.65 0.00 0.00 0.00

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Connect Biopharma Holdings (CNTB) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Connect Biopharma Holdings and its competitors.
Is Connect Biopharma Holdings' NonCurrent Deferred Liabilities too high?
Connect Biopharma Holdings' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' NonCurrent Deferred Liabilities compare to ENLV and SMNR?
Connect Biopharma Holdings' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price